Add this topic to your myFT Digest for news straight to your inbox
Top US drug regulator is accused of being too cosy with industry after approving Alzheimer’s drug
Campaigners hit out at high price for controversial treatment that has divided scientists
FDA signs off on first new treatment for disease in almost 20 years despite controversy over efficacy
FDA extends emergency authorisation after studies suggest jab is 100% effective
Regulators to give green light to inoculate adolescents in coming days
CDC and FDA recommendation comes after reports of ‘rare and severe’ blood clots
Regulator gives emergency approval to third Covid treatment and first involving a single shot
Vote by independent experts paves the way for first single-dose jab in the US
FDA report finds single-dose shot effective in preventing severe symptoms in US, Brazil and South Africa
FDA says companies could avoid lengthy trials to speed up authorisation of tweaked jabs
FDA will now weigh whether to allow use of first single-dose jab to prevent the virus
FDA veteran Janet Woodcock oversaw approval of new painkillers amid worsening epidemic
US agency go-ahead will provide boost to supplies as hospitalisations due to pandemic soar
FDA emergency authorisation will make US the first country to greenlight a second jab
US regulator expected to grant emergency authorisation for inoculation by end of week
Self-testing kit developed by Australia’s Ellume provides results in 20 minutes
FDA staff report paves the way for possible approval by end of the week
Food and Drug Administration head denies yielding to White House pressure
FDA poised for final decision after receiving endorsement from advisory committee
Trump ‘very hopeful’ regulators will grant emergency approval in US ‘within days’
Regulators on both sides of Atlantic set to decide on approval in coming weeks
The FDA issues emergency use authorisation for Regeneron’s antibody treatment
US FDA gives emergency approval to bamlanivimab therapy designed to boost immune system
Scientists express scepticism of trial data and US regulatory process at fiery hearing
International Edition